Seattle Genetics (SGEN -3.3%) says the European Commission has granted conditional marketing...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN -3.3%) says the European Commission has granted conditional marketing authorization to its collaborator Takeda Pharmaceuticals for two indications of Adcetris. The first is for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and the second for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. Under the agreement SGEN will receive two milestone payments from Millennium, one for each indication, totaling $25M.